

I wish to reiterate my total objection to the transfer to industry of the cost of processing submissions to the PBAC. I regret to have to say that the PBAC is already too close to the pharmaceutical industry and in my opinion too much influenced by its views.

This is particularly apparent in my own field of osteoporosis where expensive remedies are being subsidised by the taxpayer for virtually anyone with a fracture regardless of whether the patient has osteoporosis or not.

Any measure that increases the influence of the Industry over the PBAC should be rejected. How can a committee regulate a body on which it depends for finance?

Prof. B E C Nordin AO FRACP D Sc